Relation between falciparum malaria and bacteraemia in Kenyan children: a population-based, case-control study and a longitudinal study  by Scott, J Anthony G et al.
Articles
1316 www.thelancet.com   Vol 378   October 8, 2011
Lancet 2011; 378: 1316–23
Published Online
September 7, 2011
DOI:10.1016/S0140-
6736(11)60888-X
See Comment page 1281
Kenya Medical Research 
Institute-Wellcome Trust 
Research Programme, Kiliﬁ , 
Kenya (J A G Scott FRCP, 
J A Berkley MD, I Mwangi MMed, 
L Ochola PhD, S Uyoga MSc, 
A Macharia MSc, C Ndila MSc, 
B S Lowe MPhil, 
S Mwarumba MSc, E Bauni PhD, 
K Marsh FRCP, 
T N Williams MRCP); Nuﬃ  eld 
Department of Medicine, 
University of Oxford, Oxford, 
UK (J A G Scott, J A Berkley, 
T N Williams); INDEPTH 
Network, Accra, Ghana 
(J A G Scott, T N Williams); and 
Department of Paediatrics, 
University of Oxford, Oxford, 
UK (T N Williams)
Correspondence to:
Dr Anthony Scott, 
KEMRI-Wellcome Trust 
Programme, Centre for 
Geographic Medicine 
Research-Coast, P O Box 230, 
Kiliﬁ , Kenya
ascott@ikiliﬁ .org
Relation between falciparum malaria and bacteraemia in 
Kenyan children: a population-based, case-control study and 
a longitudinal study 
J Anthony G Scott, James A Berkley, Isaiah Mwangi, Lucy Ochola, Sophie Uyoga, Alexander Macharia, Carolyne Ndila, Brett S Lowe, 
Salim Mwarumba, Evasius Bauni, Kevin Marsh, Thomas N Williams
Summary 
Background Many investigators have suggested that malaria infection predisposes individuals to bacteraemia. 
We tested this hypothesis with mendelian randomisation studies of children with the malaria-protective phenotype 
of sickle-cell trait (HbAS).
Methods This study was done in a deﬁ ned area around Kiliﬁ  District Hospital, Kiliﬁ , Kenya. We did a matched case-
control study to identify risk factors for invasive bacterial disease, in which cases were children aged 3 months to 
13 years who were admitted to hospital with bacteraemia between Sept 16, 1999, and July 31, 2002. We aimed to match 
two controls, by age, sex, location, and time of recruitment, for every case. We then did a longitudinal case-control 
study to assess the relation between HbAS and invasive bacterial disease as malaria incidence decreased. Cases were 
children aged 0–13 years who were admitted to hospital with bacteraemia between Jan 1, 1999, and Dec 31, 2007. 
Controls were born in the study area between Jan 1, 2006, and June 23, 2009. Finally, we modelled the annual incidence 
of bacteraemia against the community prevalence of malaria during 9 years with Poisson regression.
Results In the matched case-control study, we recruited 292 cases—we recruited two controls for 236, and one for the 
remaining 56. Sickle-cell disease, HIV, leucocyte haemozoin pigment, and undernutrition were positively associated 
with bacteraemia and HbAS was strongly negatively associated with bacteraemia (odds ratio 0·36; 95% CI 0·20–0·65). 
In the longitudinal case-control study, we assessed data from 1454 cases and 10 749 controls. During the study period, 
the incidence of admission to hospital with malaria per 1000 child-years decreased from 28·5 to 3·45, with a reduction 
in protection aﬀ orded by HbAS against bacteraemia occurring in parallel (p=0·0008). The incidence of hospital 
admissions for bacteraemia per 1000 child-years also decreased from 2·59 to 1·45. The bacteraemia incidence rate 
ratio associated with malaria parasitaemia was 6·69 (95% CI 1·31–34·3) and, at a community parasite prevalence of 
29% in 1999, 62% (8·2–91) of bacteraemia cases were attributable to malaria.
Interpretation Malaria infection strongly predisposes individuals to bacteraemia and can account for more than half 
of all cases of bacteraemia in malaria-endemic areas. Interventions to control malaria will have a major additional 
beneﬁ t by reducing the burden of invasive bacterial disease.
Funding Wellcome Trust.
Introduction
Invasive bacterial diseases are a major cause of childhood 
illness and death in sub-Saharan Africa, and are sustained 
by the high prevalence of contributory risk factors such as 
HIV infection, malnutrition, and sickle-cell disease.1,2 
Similarity in the geographical and seasonal variations of 
malaria and invasive bacterial diseases, especially those 
caused by non-typhi Salmonella species, and the occasional 
detection of malaria and bacterial infections in the same 
patient has led researchers to suggest that malaria might 
also be a risk factor for invasive bacterial disease.3–5 
Ascertainment of the cause of such an association is 
diﬃ  cult, except with a randomised study of a malaria 
control intervention. In this study, however, we make 
use of the random population distribution of sickle-cell 
trait (HbAS), a phenotype that is highly protective 
against malaria,6,7 to investigate this association in an 
unbiased manner.
Methods
Study design
We did an individually matched, population-based, case-
control study of children admitted to hospital for invasive 
bacterial disease between 1999 and 2002. We recorded an 
association between HbAS and protection against 
bacteraemia after adjustment for major confounders. We 
speculated that this protection could be mediated by the 
known protection of HbAS against malaria, which would 
imply that malaria is a cause of invasive bacterial disease. 
An alternative explanation was that the recorded 
protection could be a direct genetic eﬀ ect, independent 
of malaria. Because the incidence of malaria in our study 
setting was decreasing steadily, we were able to 
distinguish between these two hypotheses by doing a 
longitudinal case-control study, repeated yearly through-
out a 9-year study period. Finally, to show the public 
health importance of malaria as a risk factor for invasive 
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bacterial disease we estimated the magnitude of the 
association between the two diseases in a longitudinal 
study of disease trends. 
Study population
The studies were done at Kiliﬁ  District Hospital (KDH), 
Kiliﬁ , Kenya. The hospital admits about 4900 children 
per year. Since 1998, routine clinical and laboratory 
data, including assessment of blood ﬁ lms for malaria, 
have been systematically recorded. All children had 
blood cultures done on admission to hospital, apart 
from those admitted for elective procedures or for 
observation after minor accidents,1 and a sample of 
blood had been stored at –80°C for a range of study-
speciﬁ c genetic tests.
In September, 2000, the Kiliﬁ  Health and Demographic 
Surveillance System (HDSS) was established in an 
891 km2 area around KDH.8 All analyses presented here 
are restricted to residents of this area. In this system, all 
births, deaths, and migration events were captured at 
home visits occurring every 4–6 months. During the 
study period, insecticide-treated bednets were introduced 
progressively into the district, and eﬀ ective combination 
antimalarial treatment became widely available.9 
Haemophilus inﬂ uenzae type b (Hib) conjugate vaccine 
was ﬁ rst introduced to the childhood immunisation 
schedule in November, 2001, and coverage for three doses 
of vaccine at 12 months was 88% when estimated in 
2004.10 In routine antenatal screening at KDH between 
August, 2004, and December, 2007, HIV prevalence was 
4·9% with no evidence of a temporal trend (χ² test for 
trend, p=0·3). In 2004, no child received co-trimoxazole 
or antiretroviral treatment, but, in 2007, 499 children 
received co-trimoxazole and 144 received antiretroviral 
treatment. By linear regression, there was no change in 
mean weight-for-age Z scores by year for all inpatients 
aged 1–59 months (p=0·5).
Written informed consent was obtained from the 
parents of all study participants. The studies were 
approved by the Kenya Medical Research Institute 
(KEMRI) National Ethical Review Committee.
Study participants and sampling methods
In the matched case-control study, we identiﬁ ed risk 
factors for invasive bacterial disease. Cases were children, 
aged 3 months to 13 years, admitted to KDH between 
Sept 16, 1999, and July 31, 2002, whose blood cultures 
grew pathogenic bacteria and who had not previously 
been enrolled. To exclude hospital-associated infections, 
children who had been discharged from hospital within 
14 days before readmission were excluded. We were 
unable to interview parents of children who died before 
their blood culture yielded a pathogen and did not recruit 
these children.
Controls were healthy children individually matched to 
cases on age, sex, and residential location, and were 
recruited within 2 weeks of their matched case being 
identiﬁ ed. For each case, two controls were sought at 
home in the community. After visiting the household of 
a case, a study ﬁ eldworker spun a pencil on the ground 
14 150 paediatric admissions
11 983 children aged 3 months to 13 years
528 with positive blood culture
369 eligible for enrolment
340 enrolled
2167 children younger than 3 months or older 
than 13 years
255 with no blood culture
11 200 with no pathogen in blood culture
42 died before culture results known
117 lived outside study area
26 discharged before enrolment
3 refused consent
32 unmatched
16 isolates later deﬁned as non-pathogenic
292 included in the analysis
Figure 1: Matched case-control study proﬁ le, 1999–2002
Case-control pairs 
(n)
Univariate 
analysis (odds 
ratio [95% CI])
Adjusted 
analysis (odds 
ratio [95% CI])
Total Discordant
Sickle-cell phenotype
HbSS 383 20 15·0 (2·30–97·9) 22·9 (2·47–211)
HbAS 483 111 0·47 (0·29–0·77) 0·36 (0·20–0·65)
HIV status (positive) 527 132 14·6 (7·10–29·8) 9·03 (3·59–22·7)
Malaria
Any parasitaemia 528 219 0·53 (0·38–0·76) ··
Parasitaemia >10 000/μL 528 78 0·75 (0·43–1·31) ··
Parasitaemia >50 000/μL 528 36 2·89 (1·25–6·70) ··
Leucocyte haemozoin pigment 524 111 3·28 (2·02–5·31) 3·52 (1·92–6·47)
Histidine-rich protein-2 >0 ng/mL 254 52 3·03 (1·52–6·07) ··
Histidine-rich protein-2 >20 ng/mL 251 12 4·80 (0·99–23·2) ··
Palpable spleen 528 194 2·01 (1·43–2·81) ··
Malnutrition
Weight-for-age Z score ≥–1·8 528 257 0·39 (0·28–0·54) ··
Height-for-age Z score ≥–1·6 528 241 0·71 (0·52–0·96) ··
Weight-for-height Z score ≥–1·1 528 252 0·43 (0·31–0·59) ··
Skin or hair changes caused by 
malnutrition
528 106 5·56 (3·15–9·81) ··
Mid-upper arm circumference (cm)* 512 243 0·54 (0·48–0·62) 0·57 (0·49–0·66)
No other exposure variable had a signiﬁ cant association with bacteraemia in the univariate analysis—these included 
pedal oedema, BCG scar, maternal ethnic group, paternal ethnic group, and maternal and paternal education level. 
*The univariate odds ratio for mid-upper arm circumference as a continuous variable was analysed by conditional 
logistic regression. The distribution of concordant and discordant cells used in the classic analysis are given in the 
webappendix p 6.
Table: Risk factors for admission to hospital with bacteraemia, 1999–2002
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and proceeded in the direction of the pencil point, 
inquiring at every house in turn until two suitably 
matched controls were identiﬁ ed. Fieldworkers then 
used a questionnaire to ﬁ nd out the following information 
about the controls: age, sex, ethnic group, and level of 
parents’ education—splenomegaly, BCG scar, foot 
oedema, anthropometry, and skin or hair changes caused 
by malnutrition were ascertained later by physical 
examination at the hospital. 
In the longitudinal case-control study, we assessed 
the relation between HbAS and invasive bacterial 
disease as malaria incidence decreased. Cases were 
bacteraemic patients aged 13 years or younger who were 
admitted to KDH between Jan 1, 1999, and Dec 31, 2007. 
Children were excluded if they were readmitted within 
6 months of a previous episode. Children who died 
before blood cultures became positive were not 
excluded. Controls were children born within the study 
area between Jan 1, 2006, and June 23, 2009, who were 
sampled systematically during home visits at age 
3–11 months as part of a cohort study of genetic 
susceptibility to infectious disease.2
Laboratory methods
Blood cultures were consistently processed in BACTEC 
Peds Plus bottles with a BACTEC 9050 automated blood-
culture instrument (Becton Dickinson, Oxford, UK). 
Positive samples were subcultured on standard media by 
routine microbiological techniques.1 Quality assurance 
was provided by the UK National External Quality 
Assessment Service. Blood was examined for malaria 
parasites by microscopy of Giemsa-stained thick and thin 
ﬁ lms. Parasite densities were calculated as parasite 
counts per 500 red blood cells (or per 100 white blood 
cells) multiplied by the relevant blood-cell concentration 
measured by Coulter counter (Beckman Coulter, High 
Wycombe, UK).
In the matched case-control study, sickle haemoglobin 
(HbS) phenotype was established by electrophoresis. Two 
ELISA tests were used to identify HIV infections, and 
discordant results were resolved by PCR, as were positive 
results from children younger than 18 months. Plasma 
concentrations of the malaria antigen histidine-rich 
protein 2 (HRP2) were measured by sandwich ELISA 
against a known concentration standard;11 HRP2 is 
secreted by red blood cells infected by Plasmodium 
falciparum and is detectable in the plasma of adult 
patients with uncomplicated malaria for 2 or more 
weeks.12 Leucocyte haemozoin pigment—a speciﬁ c 
marker of malaria disease and a stronger predictor of 
outcome in malaria than parasitaemia13—was detected 
on malaria blood-ﬁ lms.
In the longitudinal case-control study, DNA from cases 
was extracted retrospectively from frozen blood samples 
obtained on admission with Qiagen DNA blood mini kits 
(Qiagen, Crawley, UK) and typed for HbS by PCR. For 
controls, capillary blood samples were phenotyped for 
HbS by high-performance liquid chromatography 
(Variant Analyzer, BioRad, Hercules, CA) with the 
β-thalassaemia Short Program (BioRad).
Statistical analysis
The univariate analysis of the matched case-control study 
was undertaken with classical methods for matched data 
with variable controls per case.14 In the multivariable 
model, malaria and malnutrition measures were ﬁ rst 
analysed as groups, in a hierarchical design, then all 
variables signiﬁ cant at p<0·1 in ﬁ rst-level analyses were 
included in a backward stepwise conditional 
logistic regression.
We analysed data from the longitudinal case-control 
study with logistic regression, taking account of 
potential confounders—sex, ethnic group, and geo-
graphical division of residence in ﬁ ve strata. The 
analysis was done separately for each year of clinical 
surveillance. All the controls were used as the 
comparison group in each of these yearly analyses. 
Although this analysis was not adjusted for age, such 
adjustment would be unlikely to alter the odds ratios 
(OR) because the prevalence of HbAS does not vary 
much throughout childhood.
We estimated the yearly incidence of admission with 
bacteraemia or malaria by dividing the number of cases 
resident in the Kiliﬁ  HDSS study area by the mid-year 
44 416 paediatric admissions
44 375 aged 0–13 years
36 788 lived within the study area
1802 children with bacteraemia
1454 bacteraemic with sickle typing
1375 cases in a case-control study
41 children older than 13 years
7587 lived outside the study area
1137 with no blood culture
33 860 with no pathogen in blood culture
1686 non-Hib cases included in an incidence 
trend analysis
116 had Hib*
79 had sickle-cell disease
11 readmitted within 6 months
126 no stored sample for sickle typing
211 samples not suitable for typing
Figure 2: Longitudinal case-control and surveillance proﬁ le, 1999–2007 
*Cases with Haemophilus inﬂ uenzae type b (Hib) bacteraemia were excluded from the incidence trend and Poisson 
regression analyses but included in the longitudinal case-control study. 
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population. The population size in 1999 was estimated 
by log linear extrapolation from count data obtained in 
years 2000–03. Linear trends in the incidence of 
admission with malaria or bacteraemia were tested with 
Poisson regression.
The bacteraemia incidence rate ratio (IRR) associated 
with malaria para sitaemia was estimated by Poisson 
regression of the yearly incidence of bacteraemia 
against the yearly prevalence of malaria parasitaemia 
across 9 years after adjustment by calendar year. The 
yearly parasite prevalence was estimated in children 
admitted to hospi tal with trauma, as previously 
described.15 The population attributable risk fraction for 
a given malaria parasite prevalence (P) was calculated 
for each year as P(IRR – 1) / P(IRR – 1) + 1. Children with 
Hib bacteraemia were excluded from analyses of 
incidence trends, Poisson regression, and population 
attributable risk fraction, but not from the case-
control studies.
Role of the funding sources
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
Of 340 patients enrolled, we included 292 in the matched 
case-control analysis (ﬁ gure 1; webappendix p 5). We 
enrolled two matched community controls for 
236 patients, but could identify and enrol only one 
matched control for the remaining 56 patients. The 
mean diﬀ erence in age between the patients and their 
matched controls for individuals aged 2–11 months was 
1·10 (95% CI 0·4 to 1·79), 12–23 months was 0·62 (–0·18 
to 1·43), 24–59 months was –1·22 (–2·78 to 0·34), and 
≥60 months was –8·16 (–11·55 to –4·76).
The prevalence of HbAS in controls was 17·8% (93 of 
522 children). In univariate analyses, HbAS was 
negatively associated with bacteraemia (table). In the 
multivariable model, bacteraemia was positively 
associated with homozygous sickle-cell anaemia (HbSS), 
HIV, and leucocyte haemozoin pigment (table) and 
negatively associated with increasing mid-upper arm 
circumference. After adjustment for these potential 
confounders, the negative association between HbAS 
and bacteraemia increased (table). Further adjustment 
with any of the markers of malaria (any parasitaemia, 
>10 000 parasites per μL, >50 000 parasites per μL, 
presence of HRP2, HRP2 concentration >20 ng/mL, 
HRP2 concentration >44 ng/mL, splenomegaly, or 
leucocyte haemozoin pigment) did not reduce the OR for 
HbAS by more than 15% and after inclusion of the 
strongest malaria marker, leucocyte haemozoin pigment, 
none of the others made a statistically signiﬁ cant 
contribution to the ﬁ nal model (webappendix p 9).
In a repetition of the ﬁ nal model, restricted to cases of 
non-typhi salmonella  and paired controls, the OR for 
leucocyte-haemozoin pigment was 16·5 (95% CI 
3·44–79·3; webappendix p 7). To examine interactions by 
bacterial species, we stratiﬁ ed cases into four groups: 
those with Streptococcus pneumoniae (111 children), other 
Gram-positive bacteraemias (23 children), non-typhi 
salmonella (61 children), and other Gram-negative 
bacteraemias (97 children). The prevalence of leucocyte-
haemozoin pigment diﬀ ered between groups; it was 
11·7% in children with S pneumoniae, 8·7% in children 
with other Gram-positive bacteraemias, 32·8% in children 
with non-typhi salmonella, and 15·5% in children with 
other Gram-positive bacteraemias (p=0·003). The preva-
lence of HbAS did not vary signiﬁ cantly between groups 
(p=0·49, web appendix p 7).
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Figure 3: Admissions to Kiliﬁ  District Hospital for malaria in children younger than 14 years and (A) odds ratios 
for HbAS in admissions for bacteraemia and matched community controls or (B) admission to hospital for 
bacteraemia, 1999–2007
Error bars are 95% CIs.
See Online for webappendix
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Figure 2 shows the study proﬁ le for the longitudinal 
case-control study and surveillance. A pathogenic 
bacterium was isolated in 1791 children (web-
appen dix p 8)—116 of which were Hib. 76 210 children 
aged 13 years or younger lived within the Kiliﬁ  HDSS 
boundary in 1999, increasing to 111 054 in 2007. Between 
1999 and 2007, the incidence of admission to hospital 
with a positive blood-ﬁ lm result per 1000 child-years of 
observation decreased from 28·5 to 3·45, and admissions 
with bacteraemia per 1000 child-years of observation 
decreased from 2·59 to 1·45 (ﬁ gure 3; webappendix p 8). 
IRRs per year of surveillance were 0·80 (95% CI 
0·79–0·80) for malaria, 0·92 (0·91–0·94) for bacteraemia, 
0·89 (0·86–0·91) for Gram-negative bacteraemia, 0·96 
(0·94–0·98) for Gram-positive bacteraemia, 0·78 
(0·74–0·82) for non-typhi salmonella bacteraemia, and 
0·94 (0·91–0·97) for S pneumoniae bacteraemia.
1454 children were successfully typed for HbS, of 
whom 154 (11%) had HbAS and 79 (5%) had HbSS 
(ﬁ gure 2). Inpatient mortality was much the same 
between normal (HbAA) bacteraemic children 
(264 [22%] of 1220) and bacteraemic children with HbAS 
(39 [25%] of 154; p=0·30). Of 26 351 infants born in the 
Kiliﬁ  HDSS area in the study period, we visited the 
parents of 18 403 at their homes during the ﬁ rst year of 
the infant’s life—the parents of 10 884 (59%) consented 
for their infants to be screened; 10 749 were successfully 
typed for HbS, of whom 1604 (15%) had HbAS and 
95 (1%) had HbSS. With these controls as a constant 
representation of the background prevalence of HbAS, 
we calculated ORs for HbAS in cases versus controls in 
each of the years 1999–2007 (ﬁ gure 3). The OR for HbAS 
during the period overlapping the matched case-control 
study (1999–2002) was 0·47 (95% CI 0·35–0·63), which 
is identical to the unadjusted OR in the matched study. 
However, in parallel with the decreasing incidence of 
malaria, the prevalence of HbAS in cases increased 
signiﬁ cantly by calendar year (χ² test for trend: 
p=0·0008), reducing the OR for HbAS to unity. 
We explored the pathogen speciﬁ city of the association 
between HbAS and bacteraemia in 12 species groups 
(ﬁ gure 4). These analyses were restricted to the period 
1999–2005, after which malaria incidence decreased by 
more than 75% and any association is likely to be diluted. 
We recorded signiﬁ cant protective associations between 
HbAS and bacteraemia caused by ﬁ ve gram-negative 
groups (ﬁ gure 4). The OR for HbAS and pneumococcal 
bacteraemia was 0·92 (95% CI 0·67–1·28). However, 
compared with the background prevalence of HbAS in 
controls (14·9%), the prevalence in patients with 
pneumococcal bacteraemia increased from 8·9% (12 of 
135 individuals) during 1999–2002 to 19·3% (33 of 
138 individuals) during 2004–07 (p=0·01).
The IRR for bacteraemia in populations with or 
without malaria parasitaemia was 6·69 (95% CI 
1·31–34·3). This ecological analysis provides an estimate 
of eﬀ ect size but does not take account of variation in 
other risk factors for bacteraemia during the study 
period. The population attributable risk fraction for 
malaria as a cause of bacteraemia was 62% (95% CI 
8·2–91) in 1999 when the prevalence of parasitaemia in 
the study population was 29%.
Discussion
The results of our two case-control studies show that 
HbAS protects against invasive bacterial disease, that 
this protection is mediated by the known protection of 
HbAS against malaria, and therefore that malaria is a 
cause of invasive bacterial disease.
The βs mutation of the β-globin gene is a classic 
example of a balanced polymorphism in human 
populations. Children who are homozygous for the 
βs mutation (HbSS) have sickle-cell anaemia, a disorder 
associated with childhood mortality of more than 90% in 
much of Africa.2,16 Conversely, heterozygotes with HbAS 
have 50% protection against mild malaria and 
90% protection against severe malaria.6,7 The βs mutation 
has therefore been maintained at high frequencies in 
malaria-endemic areas through a balancing survival 
advantage.17 Children with HbSS have a pronounced risk 
of invasive bacterial disease,18 a ﬁ nding we substantiated 
in our matched case-control study of children admitted 
to hospital with bacteraemia. In most studies,19 children 
with HbSS are compared with all other participants 
combined, but in our study we diﬀ erentiated the 
heterozygous state, HbAS, and noted that HbAS was 
associated with signiﬁ cant protection against invasive 
bacterial disease (table). 
In a study of bacterial infections in children from the 
1960s, Eeckels and colleagues20 noted that the prevalence 
of HbAS (26 of 196 [13%]) in children presenting with 
invasive bacterial disease was substantially lower than it 
was in the local population (23%). They concluded that 
“although the diﬀ erence between observed and expected 
Escherichia coli
Other Gram-negative bacteraemia
Acinetobacter spp
Haemophilus inﬂuenzae type b
Non-typhi salmonella
Pseudomonas spp
Streptococcus aureus
Group A Streptococcus spp
Klebsiella spp
Haemophilus inﬂuenzae non-type b
Other Gram-positive bacteraemia
Streptococcus pneumoniae
0·07 0·1 0·2 0·3
Odds ratio (95% CI) for HbAS
0·5 0·7 1 2 3
Figure 4: Odds ratio for sickle-cell trait in cases with bacteraemia compared with community controls in the 
longitudinal case-control study, by type of bacteraemic pathogen (1999–2005)
Children infected with more than one species of bacteraemic pathogen were included in analysis for each species 
or group.
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frequencies is not statistically signiﬁ cant, the possibility 
that sickle-cell trait is linked with a lowered sensitivity to 
bacterial infections must be considered”.20
Our substantiation of this ﬁ nding suggested two 
potential hypotheses. First, that HbAS is independently 
protective against invasive bacterial disease through 
genetic pleiotropy or linkage disequilibrium. Second, 
that the eﬀ ect of HbAS on such bacterial disease is 
mediated by protection against malaria and, therefore, 
that malaria itself is a risk factor for invasive bacterial 
disease. We originally planned to distinguish between 
these two hypotheses by repeating the case-control study 
in a population that had a similar prevalence of HbAS 
but no malaria. However, because the incidence of 
hospital admissions for malaria was decreasing sharply 
on the Kenyan coast, we were able to repeat the study at 
the same site. 
In the longitudinal case-control study we recorded that, 
in parallel with the decreasing incidence of malaria, the 
prevalence of HbAS in patients with invasive bacterial 
disease increased signiﬁ cantly by calendar year, reducing 
the OR for HbAS to unity. This ﬁ nding eﬀ ectively 
eliminates pleiotropy or linkage disequilibrium as 
alternative explanations for the protective association 
between HbAS and invasive bacterial disease. Although 
the possibility of confounding by factors that we have not 
considered remains, any factor that could explain this 
trend would have to satisfy three criteria: it must have 
increased or decreased steadily between 1999 and 2007, it 
must be associated with HbAS, and it must be 
independently associated with the incidence of 
bacteraemia. Malaria clearly satisﬁ es the ﬁ rst two criteria; 
previous studies4,21,22 and biological theory suggest that it 
also satisﬁ es the third.
A plausible biological link between malaria and invasive 
bacterial disease has previously been suggested, although 
most work has focused on salmonellosis. First, malaria 
causes haemolytic anaemia, a mechanism believed to be 
important in the increased susceptibility to invasive 
salmonellosis in children with bartonellosis or sickle-cell 
disease.4,21 Experimentally induced haemolysis also 
increases susceptibility to salmonellosis in mice.23 
Second, accumulation of haemozoin pigment in 
monocytes impairs diverse macrophage functions, 
inhibiting expression of intercellular adhesion molecule-1, 
integrin-CD11c, and MHC class II antigens, delaying 
diﬀ erentiation into functional antigen-presenting cells, 
and stimulating proinﬂ ammatory cytokines and 
chemokines.24 Each of these functions has a role in 
antibacterial immunity. Third, severe malaria leads to 
bacterial seeding of the bloodstream because of 
microvascular parasite sequestration in gut mucosa.25 As 
noted elsewhere,26 this ﬁ nding suggests a broader 
susceptibility to bacteria that colonise the gut, rather than 
to Salmonella spp in particular.
We explored the eﬀ ect of malaria on the risk of invasive 
bacterial disease caused by 12 diﬀ erent bacterial species 
in the longitudinal case-control study. We recorded 
signiﬁ cant associations between only gram-negative 
bacteraemia and HbAS. Use of HbAS as a simple marker 
of malaria protection might not be valid for pneumococcal 
bacteraemia because in the absence of malaria HbAS is 
weakly associated with the risk of pneumococcal disease.27 
In children with pneumococcal bacteraemia, we recorded 
a signiﬁ cant variation in the prevalence of HbAS during 
periods of high and low malaria parasitaemia. In the 
absence of malaria, children with HbAS seem to have 
some of the direct susceptibility to pneumococcal 
bacteraemia associated with HbSS, but in the presence 
of malaria this risk is small in relation to their indirect 
protection against pneumococcal disease because of their 
reduced susceptibility to malaria.
We used Poisson regression to estimate the magnitude 
of the association between HbAS and bacteraemia in an 
ecological study design. Although this analysis is 
susceptible to secular trends in confounding variables, 
little variation occurred during the study period in the 
prevalence of major known confounders, such as HIV 
and malnutrition. Furthermore, introduction of co-
tri moxazole and antiretroviral drugs for children with HIV 
infection did not occur until after 2004 and were available 
to only a small proportion of the HIV-infected population.
Panel: Research in context
Systematic review
We systematically searched PubMed up to June 8, 2011, with 
the search terms “bacterial infections”[MeSH] and “malaria, 
falciparum”[MeSH], which we supplemented with secondary 
citations and our personal collections. We did not identify any 
studies of the quantitative relation between malaria and 
invasive infections caused by speciﬁ c bacterial pathogens. 
Interpretation
A link is widely speculated to exist between malaria and 
invasive bacterial disease, but it has never been proven 
epidemiologically. In this 9-year study, we investigated this 
association through a novel mendelian randomisation 
approach with the malaria-protective phenotype of sickle-cell 
trait. Our ﬁ ndings show that the sickle-cell trait gave strong 
protection against all-cause bacteraemia at a time when 
malaria was common, but that this association decreased in 
parallel with the falling incidence of malaria. We conclude 
that the protective eﬀ ect of sickle-cell trait against 
bacteraemia is mediated by its ability to confer resistance to 
malaria, conﬁ rming  a causal link between malaria and 
bacteraemia. In modelling this relation, we estimate that, 
when the prevalence of Plasmodium falciparum infection was 
29% in our study population, more than half of all 
bacteraemic infections were attributable to malaria. 
Strategies that focus on the prevention of childhood malaria 
will therefore have a disproportionately large eﬀ ect on 
all-cause childhood mortality.
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Our ﬁ ndings provide convincing evidence that malaria 
predisposes children to the development of invasive 
bacterial disease (panel), and we estimate the magnitude 
of this association as an increase in rate of 6·7 times. In 
Kiliﬁ , bacteraemia is a serious disease with a mortality 
of 22% despite prompt treatment with intravenous anti-
biotics and supportive treatment. Mortality associated 
with invasive bacterial disease is likely to accentuate the 
survival advantage of the HbAS phenotype and sustain 
the frequency of the βs mutation  in Africa at levels 
much greater than would have occurred without a high 
background incidence of invasive bacterial disease. 
Several lines of evidence already lend support to the 
idea that malaria indirectly causes deaths normally 
attributed to other causes. Elimination of malaria from 
Guyana and Sri Lanka, and control of malaria in Bioko 
Island, Equatorial Guinea, led to much greater 
reductions in mortality than were predicted from 
estimates of malaria-related deaths before the 
interventions.22,28,29 A similar occurrence was recorded 
in a randomised controlled trial of insecticide-treated 
bednets.30 Mathematical models of the magnitude of 
the survival advantage of HbAS needed to match the 
recorded gene frequencies of the βs mutation in Africa 
predict much greater malaria mortality than that 
directly measured,31 and models of malaria mortality ﬁ t 
epidemiological data from Africa only when indirect 
mortality is accounted for.32
We have previously reported from Kiliﬁ —during a 
period of high malaria parasite prevalence—that 
invasive bacterial disease caused at least as many 
inpatient deaths as did malaria.1 If, as we estimate 
here, more than half of these same cases of invasive 
bacterial disease are attributable to infection with 
P falciparum, then the control of malaria in tropical 
Africa will lead to substantial additional beneﬁ ts 
through an indirect reduction of childhood mortality 
from invasive bacterial diseases.
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